ArticleCardiology2026
Soluble ST2 as an Independent Predictor of Post-Discharge New-Onset Atrial Fibrillation in Patients with ST-Elevation Myocardial Infarction.
Article in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNew-onset atrial fibrillation (NOAF) represents a significant complication following ST-elevation myocardial infarction (STEMI). Soluble suppression of tumorigenicity 2 (sST2) is a biomarker reflecting myocardial stress and fibrosis. However, its predictive value for post-discharge NOAF in STEMI patients remains inadequately characterized. This study was to investigate whether elevated sST2 levels during hospitalization independently predict post-discharge NOAF in STEMI patients.
methodsThis multicenter, prospective cohort study enrolled 648 consecutive STEMI patients. Serum sST2 concentrations were measured within 24 h of admission using ELISA. Multivariable logistic regression, receiver operating characteristic (ROC) curve analysis, and risk reclassification metrics were employed to assess sST2's predictive performance.
resultsNOAF occurred in 56 patients (8.64%) during follow-up. Patients developing NOAF exhibited significantly higher sST2 levels compared to those without NOAF (62.84 ± 54.62 vs. 30.37 ± 34.71 ng/mL, p < 0.001). After adjusting for confounders, sST2 remained an independent predictor of NOAF (OR = 1.02, 95% CI: 1.01-1.02, p < 0.001). The area under the ROC curve for sST2 was 0.785 (95% CI: 0.723-0.848). Incorporating sST2 into the clinical model significantly improved discrimination (AUC from 0.718 to 0.810, p < 0.001) and risk reclassification (NRI = 0.084, p = 0.033; IDI = 0.047, p = 0.003). Restricted cubic spline analysis revealed a nonlinear dose-response relationship between sST2 and NOAF risk.
conclusionElevated sST2 levels during hospitalization independently predict post-discharge NOAF in STEMI patients, offering incremental prognostic value beyond traditional risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.